Monoclonal Antibody Approved to Treat Ebola
- PMID: 33755619
- DOI: 10.1097/01.NAJ.0000742484.81331.b2
Monoclonal Antibody Approved to Treat Ebola
Abstract
Ansuvimab-zykl (Ebanga), a human monoclonal antibody, has been approved to treat Zaire ebolavirus (Ebolavirus) infection.The most common adverse effects of the drug are fever, tachycardia, diarrhea, vomiting, hypotension, tachypnea, and chills; these are also common symptoms of Ebolavirus infection.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
References
REFERENCE
-
- Mulangu S, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019;381(24):2293–303.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
